Skip to main content
Equibles
LGVN logo

LGVN · Longeveron Inc. · Metrics

Track LGVN — free

Use LGVN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research LGVN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$6.58 -0.07 (-1.05%) At close · Sep 9
Rebalance outlook locked
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“We have prepared a cash flow forecast which indicates that we do not have sufficient cash to meet our minimum expenditure commitments for one year from the date these financial statements are available to be issued and therefore we need to raise additional funds to continue as a going concern. As a result, there is substantial doubt about our ability to continue as a going concern.”
View the 10-Q filed Aug 12, 2026
Market Cap
$21.27M
Shares
3.19M

LGVN metrics

49 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$6.65
Market cap
$21.27M

Price action

20 metrics
Price change (1W)
-1.5%
Price change (30D)
-2.2%
Price change (3M)
—
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
—
Annualized volatility (3M)
—
Beta
—
RSI (14D)
—
Price vs SMA 50
—
Price vs SMA 200
—
Avg volume (3M)
—
Relative volume
—
Average dollar volume
—

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
3.19M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
17.9×
reciprocal yield 5.6%
P / book
2.0
reciprocal yield 48.9%
FCF yield
-96.6%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-110.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
64.0×
reciprocal yield 1.6%
EV / revenue historical average (5Y)
64.0×
reciprocal yield 1.6%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-12

Profitability

9 metrics
Gross margin
69.8%
Operating margin
-1,992.8%
Trailing 12 months
Net margin
-1,977.6%
Gross profit (TTM)
$828,000
Operating profit (TTM)
−$23.66M
Net income (TTM)
−$23.47M
Trailing 12 months
Diluted EPS (TTM)
$-10.00
FCF margin
-1,729.9%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
—

Growth

11 metrics
Revenue growth YoY
-9.2%
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.19M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+109.0%
Year over year · more shares
Revenue CAGR (3Y)
-0.6%
Revenue CAGR (5Y)
-26.6%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-225.7%
Return on assets
-151.6%
Debt / equity
—
Current ratio
2.6
EBITDA (TTM)
−$22.86M
Free cash flow (TTM)
−$20.53M
Quick ratio
2.6
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$10.08M
Total assets
$15.49M
Total debt
$148,000

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$20.37M
Capital expenditures (TTM)
$160,000
R&D (TTM)
$12.09M
SG&A (TTM)
—
Stock compensation (TTM)
$1.58M
R&D / revenue
1,018.1%
Stock compensation / revenue
132.8%

Ownership (13F)

3 metrics
13F filers
39
13F filer change QoQ
+8
Institutional ownership
14.9%

Short interest

3 metrics
Short interest
5.3%
Latest settlement · 3.4 days to cover
Days to cover
3.4d
Short-squeeze score
63 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1721484 CUSIP 54303L203 13F (30d) 27 filings 27 filers Visit website Investor relations